Last updated: February 14, 2026
What is NDC 70710-1114?
NDC 70710-1114 corresponds to Cenobamate (Inovelon), an antiepileptic drug approved by the FDA in 2019 for the treatment of partial-onset seizures in adults. As a relatively new therapy, it enters a specialized market with established competitors such as carbamazepine, lamotrigine, levetiracetam, and lacosamide.
Market Landscape Overview
Market Size & Growth
The global epilepsy treatment market was valued at approximately USD 4.8 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 4% through 2030[1]. The U.S. accounts for roughly 40% of this market, driven by higher diagnosis rates and drug utilization.
Key Competitors
- Carbamazepine
- Lamotrigine
- Levetiracetam
- Lacosamide
- Topiramate
Market Penetration Dynamics
Because Cenobamate was approved in 2019, its adoption remains limited but increasing. Early prescriber feedback emphasizes its efficacy and tolerability, especially for patients unresponsive to other therapies.
Market Access and Reimbursement Environment
The drug's inclusion in Medicare Part D and commercial formularies depends on payer negotiations. Pricing strategies consider generic competition, especially as patents expire for older medications.
Price Analysis
Current Pricing Data
Based on publicly available wholesale acquisition cost (WAC) and average wholesale price (AWP) figures:
| Pricing Metric |
Estimated USD |
Notes |
| WAC per 100 mg |
$10.50 |
Estimated for developed markets |
| WAC per 300 mg |
$31.50 |
Scaling proportionally |
| Average Wholesale Price (AWP) |
Approximately 10% higher than WAC |
Common markup for pharmacies |
The typical dosing regimen ranges from 200 mg to 400 mg daily, translating to a monthly cost of approximately USD 300-600 for a standard outpatient prescription.
Comparison with Competitors
| Drug |
Approx. Monthly Cost |
Status |
| Cenobamate |
USD 300-600 |
New entrant |
| Levetiracetam (Keppra) |
USD 250-500 |
Mature, generic availability |
| Lamotrigine (Lamictal) |
USD 150-300 |
Generic widely available |
| Lacosamide (Vimpat) |
USD 400-700 |
Branded, prescription-only |
Note: Prices are approximate and vary by provider, region, and contractual discounts.
Price Projections
Near-Term (1-2 Years)
- Pricing stability: WAC likely to remain around current levels as competition keeps prices in check.
- Market penetration: Expected to reach approximately 5-10% of the partial-onset seizure market within 2 years[2].
Long-Term (3-5 Years)
- Pricing trends: Possible decreases as generic versions emerge post-patent expiration (if applicable); perhaps a 15-25% reduction.
- Market share growth: Projected expansion as clinicians become more familiar with efficacy and safety profile.
Regulatory and Patent Considerations
- Patent landscape: The original composition patent expires around 2030, opening opportunities for generics.
- Regulatory pathway: Potential for supplemental indications may increase market size and justify higher pricing initially.
Key Takeaways
- NDC 70710-1114 (Cenobamate) is a new but growing player in the epilepsy market.
- Pricing is currently aligned with other branded antiepileptics, with monthly costs around USD 300-600.
- Market growth hinges on prescriber acceptance, reimbursement policies, and eventual generic entry.
- Long-term pricing will decline as patents expire and generics penetrate, increasing competition.
- Despite being recent, Cenobamate has the potential for substantial market share growth due to its efficacy profile.
FAQ
1. What is the potential annual revenue for Cenobamate?
Based on current market share estimates and monthly pricing, annual revenue could range from USD 100 million to USD 300 million in the U.S. alone over the next 3 years.
2. Will pricing decline with generic versions?
Yes, generic entry typically leads to a 50-70% price reduction, depending on competition and market dynamics.
3. Are there special reimbursement considerations?
Reimbursement depends on insurer policies. Early coverage has been positive, especially in formulary tiers that favor cost-effective therapies.
4. What factors could influence market share?
Prescriber acceptance, clinical efficacy data, safety profile, insurance coverage, and competitive positioning shape market penetration.
5. How does Cenobamate differentiate itself?
It offers rapid seizure reduction and a favorable side-effect profile compared to some older antiepileptics, potentially expanding its use.
References
- Market Research Future, "Epilepsy Treatment Market Analysis," 2022.
- IQVIA, "US Epilepsy Market Dynamics," 2022.
- FDA, "Approval Calendar and Product Label," 2019.
- GoodRx, "Average Pharmacy Prices," 2023.
[1] Market size estimates and growth projections.
[2] Prescriber adoption and market share forecasts.
